This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
The researchers compared the short-term tumor regression rate, side effects and quality of life improvement between the two groups. Efficacy was based on World Health Organization standards and included those patients who had a complete response (CR0% tumor disappearance) or a partial response (PRP% to 0.05).
We care about your feedback. Let us know how we can improve your CancerCompass experience.